Lantern Pharma Inc Stock Price, News & Analysis

Lantern Pharma (NASDAQ:LTRN) has received a notice of allowance from the European Patent Office for LP-284, its AI-developed cancer therapy. The patent, extending through early 2039, covers the composition of matter for LP-284, which targets B-cell lymphomas and other B-cell malignancies.

LP-284, developed using Lantern's RADR® AI platform, is currently in Phase 1 clinical trials with potential completion in late 2025. The drug has received Orphan Drug Designations from the FDA for both mantle cell lymphoma (MCL) and high-grade B-cell lymphomas (HGBL). The therapy addresses a $4 billion annual market for blood cancers.

The development of LP-284 was notably efficient, achieving clinical trial readiness in under three years at a cost of $1.5 to $2.0 million. The patent complements existing protections in the US, Japan, India, and Mexico, with pending applications in other key markets.

Lantern Pharma (NASDAQ:LTRN) has launched an innovative AI-powered module within its RADR® platform to predict the effectiveness of combination cancer treatments. The module, trained on 221 clinical trials, focuses on DNA damaging agents (DDAs) and DNA repair inhibitors (DDRis), targeting a $50+ billion market growing at 8.5% annually through 2030.

The AI system has already demonstrated success by guiding an FDA-cleared Phase 1B/2 trial design combining LP-184 with olaparib for triple-negative breast cancer. The platform analyzes genomic, transcriptomic, and clinical data to predict drug synergies and identify optimal patient populations, potentially reducing development timelines and costs by one-third compared to traditional methods.

Key findings include an 80% positive outcome rate in non-PARP DDRi combinations, particularly with WEE1 inhibitors and platinum agents in TP53-mutated cancers.

Lantern Pharma (NASDAQ: LTRN) reports a remarkable clinical outcome from its Phase 2 HARMONIC trial, where a 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) achieved a complete response using LP-300 with standard chemotherapy. The patient, who had previously failed three treatment lines including Keytruda, radiation, and Tagrisso, showed a 57% tumor reduction initially, followed by complete response in lung and adrenal gland lesions. After 21 treatment cycles over nearly two years, the patient maintains the response with no significant adverse reactions. This success is particularly significant for never-smokers with NSCLC, a growing patient population representing a $4+ billion market opportunity. Never-smoking NSCLC cases have increased from 15% in the 1970s to 33% in the 2000s, marking the fifth leading cause of cancer-related deaths globally.

Lantern Pharma (NASDAQ: LTRN) presented promising preclinical data for LP-184 in treating atypical teratoid rhabdoid tumors (ATRT), a rare pediatric brain cancer. The data, presented at SNO's Pediatric Conference by Johns Hopkins researchers, showed significant survival improvements in mouse models: 345% increase (89 vs 20 days) in the CHLA06 model and extended survival in the BT37 model (98 vs 68 days). LP-184 demonstrated potent anti-tumor activity across multiple ATRT subtypes, with IC50 values of 17.5-161 nM, strong blood-brain barrier penetrance, and no apparent toxicity. This data validates Lantern's FDA Rare Pediatric Disease Designation and supports their planned pediatric clinical trial, expected to begin in late 2025 or early 2026, following completion of ongoing adult solid tumor trials.

Lantern Pharma (NASDAQ: LTRN) reported Q1 2025 financial results and key developments. The company is nearing completion of LP-184 Phase 1a trial enrollment with 62-65 patients by June 2025. Their LP-300 HARMONIC Trial in never-smoker NSCLC patients showed promising preliminary results with 86% clinical benefit rate and 43% objective response rate. The company's RADR® AI platform expanded to 200 billion oncology-focused data points, with new modules for ADC development. Financial position remains stable with $19.7 million in cash and equivalents as of March 31, 2025, providing runway through May 2026. Q1 2025 showed reduced net loss of $4.5 million ($0.42/share) compared to $5.4 million ($0.51/share) in Q1 2024. R&D expenses decreased to $3.3 million from $4.3 million year-over-year, while G&A expenses remained stable at $1.5 million.

Lantern Pharma (NASDAQ: LTRN) has received FDA clearance for its IND application amendment to begin a Phase 1b/2 clinical trial of LP-184 in non-small cell lung cancer (NSCLC). The trial will evaluate LP-184 in combination with immune checkpoint inhibitors (nivolumab and ipilimumab) in patients with KEAP1 and/or STK11 mutations and low PD-L1 expression. LP-184, developed using Lantern's AI platform RADR®, is a synthetically lethal small molecule that shows promise in treating this specific patient population, which currently has limited treatment options and a median survival of just 15 months. The targeted market opportunity exceeds $2 billion annually. Preclinical studies show LP-184's effectiveness correlates with PTGR1 expression levels, which are elevated in about 35% of lung cancer patients, particularly those with KEAP1 mutations.

Lantern Pharma (NASDAQ: LTRN), an AI-driven pharmaceutical company focused on developing targeted cancer therapies, has scheduled its first quarter 2025 operating and financial results webcast for Thursday, May 15, 2025, at 9:00 a.m. ET. The company's CEO, Panna Sharma, along with other management team members, will discuss Q1 2025 results and provide updates on upcoming milestones, clinical trials, and developments of their proprietary RADR® AI and machine learning platform. The webcast will be available for replay on the company's investor relations website after the call.

Lantern Pharma (LTRN) has received FDA clearance for its IND application to begin a Phase 1b/2 clinical trial of LP-184 in Triple Negative Breast Cancer (TNBC). The trial will evaluate LP-184 through two approaches: a monotherapy arm with approximately 30 advanced-stage TNBC patients, and a combination therapy with olaparib for second-line TNBC patients with BRCA1/2 alterations. LP-184, developed using Lantern's AI platform RADR®, is a novel small molecule that targets DNA damage in cancer cells. The drug previously received FDA Orphan Drug Designation (2023) and Fast Track Designation (2024) for TNBC treatment. The trials will be conducted in the US, India, and Nigeria, targeting regions with high TNBC incidence. The global TNBC market opportunity exceeds $4 billion annually, with over 300,000 new cases diagnosed worldwide each year.

Lantern Pharma (NASDAQ: LTRN) reported its Q4 and full-year 2024 results, highlighting significant progress in its AI-driven oncology drug development programs. The HARMONIC™ trial for LP-300 showed an impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with expansion in Japan and Taiwan. LP-184 received two FDA Fast Track Designations for Glioblastoma and Triple Negative Breast Cancer, plus three Rare Pediatric Disease Designations.

The company's RADR® AI platform surpassed 100 billion oncology-specific data points in 2024. Financial results showed cash position of $24.0 million as of December 31, 2024. Q4 net loss was $5.9 million ($0.54 per share), compared to $4.2 million ($0.39 per share) in Q4 2023. Full-year 2024 net loss per share was $1.93 versus $1.47 in 2023.